ReviewInternational journal of oncology2026
Cancer stem cell heterogeneity‑inspired therapeutics for enhancing tumor treatment outcomes (Review).
Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cancer stem cells and drug resistance in cancer: molecular mechanisms and therapeutic targets.Molecular biomedicine · 2026Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs), a small subpopulation of cancer cells that exhibit stem‑like properties, possess the ability to differentiate and self‑renew. These capabilities enable CSCs to act as tumor‑initiating cells, driving tumorigenesis and proliferation, leading to major clinical challenges. Specifically, CSCs play a crucial role in metastasis, recurrence and drug resistance, thereby leading to complications in therapeutic responses. The plasticity of CSCs leads to heterogeneity, allowing them to adopt diverse phenotypes in response to intrinsic genetic factors or extrinsic environmental cues. This adaptability may serve as a mechanism for CSCs to thrive in the tumor microenvironment (TME) and promote tumor progression. The present article aimed to review the multifaceted nature of CSCs, examining their functional diversity, biomarkers and interactions with the TME. Through elucidating the mechanisms that underlie this heterogeneity, researchers aim to develop targeted therapeutic interventions against CSCs, thereby enhancing the efficacy of cancer treatments and improving patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.